Screener
BioMarin Pharmaceuticals BMRN Compensation and benefits
Compensation and benefits at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 114,049 | 40,632 |
| Non-cash interest expense | 27,912 | 1,320 |
| Stock-based compensation | 119,152 | 85,231 |
| Impairment of assets | — | 2,967 |
| Deferred income taxes | 2,261 | 61,771 |
| Unrealized foreign exchange gains | (4,046) | (5,306) |
| Other | (5,534) | (4,633) |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's compensation and benefits?
- BioMarin Pharmaceuticals (BMRN) reported compensation and benefits of $75.69M in Q2 2026.
- How has BioMarin Pharmaceuticals's compensation and benefits changed year-over-year?
- BioMarin Pharmaceuticals's compensation and benefits increased by 59.3% year-over-year, from $47.53M to $75.69M.
- What does compensation and benefits mean?
- Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.
Ask your AI about BioMarin Pharmaceuticals's compensation and benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude